Background. In biliary atresia mechanisms of progressive liver injury leading to need of liver transplantation after successful portoenterostomy remain unknown. A better understanding is a prerequisite for development of novel therapies to extend native liver survival, and we aimed to unravel molecular characteristics of liver injury after successful portoenterostomy. Methods. Liver biopsies obtained from 28 biliary atresia children during successful portoenterostomy and at median age 3.0 years were studied. Biopsies were analyzed for histology and immunohistochemical expression of collagen 1, myofibroblast marker a-smooth muscle actin, and cytokeratin-7 positive ductal reactions. Hepatic ribonucleic acid (RNA) expression of growth factors and inflammatory cytokines was evaluated. Intestinal failure patients with comparable liver fibrosis and nonfibrotic gallstone patients and donor livers were controls. Results. After successful portoenterostomy, histologic cholestasis resolved and portal inflammation reduced, while fibrosis along with ductal reactions and overexpression of collagen and a-smooth muscle actin persisted. At follow-up, liver RNA expression of collagen and platelet-derived growth factor was increased, whereas RNA expression of various inflammatory cytokines remained low. Disappearance of periductal asmooth muscle actin expression after successful portoenterostomy (36% of patients) associated with contracted ductal reactions and reduced progression of fibrosis, collagen accumulation, platelet-derived growth factor RNA expression, and serum levels of bile acids and bilirubin. Fibrosis progressed less rapidly in syndromic than in isolated biliary atresia patients. Conclusion. These findings suggest that instead of inflammation, molecular signature of active fibrogenesis in association with ductal reactions prevails in long-term native liver survivors with biliary atresia. Patients should be stratified for isolated and syndromic disease forms in interventional studies. (Surgery 2017;162:548-56.) 
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Activation of portal fibroblasts and hepatic stellate cells (HSCs) into collagen-producing and a-smooth muscle actin (a-SMA) expressing myofibroblasts plays a crucial role in liver fibrogenesis. 12, 13 Reactive biliary epithelial cells of ductal reactions, the characteristic proliferation of bile ductules in response to cholestasis, may be particularly important mediator of liver fibrogenesis in BA through metaplasia, although the exact source of these cells remains unclear.
14-16 Expansion of cytokeratin-7 (CK-7) positive ductal reactions associate with decreased native liver survival, progressive fibrosis, and increased expression of matrix metalloproteinase-7. [17] [18] [19] Increased hepatic expression of collagen 1 and a-SMA at time of PE correlates with reduced native liver survival. 20, 21 Platelet-derived growth factor (PDGF) is probably the most potent mitogen for myofibroblasts and is markedly upregulated during liver fibrogenesis. 12, 13, 22 This study aimed to explore molecular characteristics of liver injury following SPE, when the patients are not cholestatic and display mostly intermediate stage of liver fibrosis exhibiting the greatest potential for its efficacious manipulation. We hypothesized that the livers of long-term survivors after SPE display a molecular signature of active fibrogenesis despite limited inflammation. For this, we assessed liver histology as well as protein and gene expression of profibrotic and inflammatory mediators in BA patients during and after SPE in relation to fibrotic and nonfibrotic controls. As isolated and syndromic BA patients most likely have diverse etiologies, we also compared progression of fibrosis between these subgroups.
MATERIALS AND METHODS
Patients and controls. In Helsinki University Hospital of Finland, 51 BA patients were treated between 1991 and 2013. Thirty (59%) normalized serum bilirubin below 20 mmol/L after SPE, and 28 (93%) were enrolled. They underwent serum sampling and liver biopsy as described previously. 19 Clinical data. Serum samples were analyzed for platelets, total and direct bilirubin, bile acids, alanine aminotransferase (ALT) and aspartate aminotransferase (AST). AST to platelet ratio index (APRI) was calculated as follows: (AST, U/ L)/50)/platelet count (E9/L)] x 100. 23 Syndromic BA was defined by the presence of any associated congenital structural malformation and BA splenic malformation (BASM) was defined as the presence of poly-or asplenia. 24 Liver histology and immunohistochemistry. Percutaneous core needle liver biopsies were obtained under ultrasound guidance as a part of the follow-up protocol when patients were anesthetized for endoscopic variceal surveillance. No biopsy-related complications were recorded. Biopsies were fixed in formalin, embedded in paraffin, sliced, and stained as described previously. 19 Twenty-four operative wedge liver biopsies obtained at PE and 28 core needle follow-up biopsies were analyzed semiquantitatively by 2 experienced pediatric liver pathologists blinded to clinical data. Fibrosis was analyzed according to the Metavir fibrosis stage (0 = no fibrosis, 1 = fibrous expansions of portal areas, 2 = portal-to-portal fibrosis, 3 = portal-to-portal and portal-to-central fibrosis, or 4 = cirrhosis). Portal inflammatory cell infiltration and intracanalicular cholestasis were graded as 0 = absent or minimal, 1 = mild, 2 = moderate, or 3 = marked.
Monoclonal antibodies for immunostaining were clone I-8H5 (Abnova corporation, Taipei City, Taiwan) for collagen 1 and clone 1A4 (DakoCytomation, Glostrup, Denmark) for a-SMA. Immunostaining for CK-7 was performed using a rabbit antihuman monoclonal antibody and ultraView Universal DAB Detection kit (Ventana, Tucson, AZ). Core needle biopsies were photographed as a whole and 5 random images from wedge biopsies were taken matching the surface area of core needle biopsies. The proportion of the antibody-positive area to the whole surface area of the biopsy (area fraction) was calculated for CK-7, collagen 1, and a-SMA with ImageJ (Bethesda, MD) Image Analysis Software (SciJava Common open source software). Ductal reaction was visualized by CK-7 expression in proliferative bile ductules, adjacent periportal hepatocytes, and bile ducts. Leica DM RXA microscope (Leica Microsystems GmbH, Wetzlar, Germany) was used for grading of immunostainings, which were performed by primary author (A.K.), blinded to clinical data. Localization and intensity of immunostaining were analyzed semiquantitatively; collagen 1: 0 = slight expression at portal areas, 1 = expanded expression at portal areas, 2 = portal-to-portal, and 3 = portal-to-central, or 4 = extended nodular expression (cirrhosis). a-SMA: 0 = staining in smooth muscle cells within portal vessel walls only, 1 = mild or moderate periportal expression with 2 = mild or moderate, or 3 = strong bridging between portal tracts, 4 = marked portal expression in the entire portal area with portal bridging (modified from Olynyk et al 25 ). Periductal a-SMA staining surrounding bile ducts and ductal proliferations was analyzed dichotomously.
Ribonucleic acid expression analyses. 
RESULTS
Patient characteristics. Median age was 61 (40-84) days at PE and 3.0 (2.1-6.7) years at follow-up. Half of the patients were males and 12 (43%) had associated structural anomalies, including cardiac defects (at least a septal defect; n = 8), polysplenia (n = 8), vascular anomalies (n = 4), intestinal malrotation (n = 5), pancreatic anomalies (n = 3), and situs inversus (n = 1). One patient had Sotos syndrome, a rare genetic disorder with excessive physical growth and mild intellectual disability. Eight patients (29%) had BASM. At follow-up 32% had splenomegaly, and 50% had developed clinical signs of portal hypertension.
Evolution of liver histology and ductal reaction after successful PE. Liver histology and biochemistry at PE and at follow-up are shown in Table I . After PE, histologic cholestasis and hyperbilirubinemia resolved and portal inflammation significantly reduced, while Metavir fibrosis stage and the magnitude of ductal reactions remained unchanged.
Immunohistochemistry of profibrotic and endothelial markers. Liver expression of collagen 1 and a-SMA in BA patients, intestinal failure controls with comparable Metavir fibrosis stage and donor liver controls without fibrosis are shown in Table II . BA patients showed markedly increased collagen and a-SMA expression compared with control donor livers. Collagen area fraction and a-SMA grading were significantly greater in BA patients than in intestinal failure controls. Collagen expression was comparably increased in the portal areas of BA patients and intestinal failure controls, but more extensive bridging between portal and central areas was observed in BA, explaining the greater area fraction in BA. Because localization and intensity of a-SMA staining concentrated more to portal and periductal areas in BA patients than in intestinal failure patients, no statistical difference in a-SMA area fraction was observed between the groups despite increased a-SMA grade in BA. Indeed, as shown in Table II and Fig, none of the fibrotic controls showed periductal a-SMA expression, compared with 100% of BA patients at SPE and 64% at follow-up (P = .001 versus controls).
At follow-up, the magnitude of ductal reactions correlated positively with the degree of a-SMA (r = 0.650, P = .001) and collagen expression (r = 0.553, P = .003), while expression of collagen and a-SMA were interrelated (r = 0.812, P < .001). Notably, the age at follow-up was unrelated to expression of collagen 1 (r = À0.085, P = .667) or a-SMA (r = À0.129, P = .539).
Hepatic expression of profibrotic and proinflammatory genes. Liver RNA expression of profibrotic and proinflammatory genes in BA patients at follow-up, fibrotic intestinal failure controls, and cholelithiasis controls without liver fibrosis are shown in Table III . Liver RNA expression of COL1A2 encoding for collagen 1 and PDGFA encoding for PDGF subunit A was significantly increased in BA compared with both control groups, while the increase in ACTA2 encoding for a-SMA remained insignificant in relation to intestinal failure patients. In follow-up BA specimens, RNA expression of COL1A2 correlated positively with collagen (r = 0.475, P = .019) and a-SMA area fraction (r = 0.512, P = .013), while PDGFA RNA expression correlated positively with collagen area fraction (r = 0.673, P < .001) and a-SMA grade (r = 0.625, P = .002) and presence of periductal a-SMA expression (Table IV) .
Of the Th1 pro-inflammatory cytokine genes, RNA expression of IL1A and IL1B encoding for interleukin (IL)-1 did not differ between BA patients and nonfibrotic controls, but was even lower in BA patients than in intestinal failure controls. There were no differences between groups in RNA expression of TNF and IFNG encoding for tumor necrosis factor and interferon gamma (Table  III) . Of the Th2 inflammatory cytokine genes, RNA expression of IL10 encoding for antiinflammatory IL-10 similarly decreased in BA and intestinal failure. RNA expression of IL4 and IL5 was comparable in different groups.
Periductal a-SMA expression associated with ductal reaction and fibrosis. Periductal a-SMA expression was observed in all patients at time of BA at follow-up* n = 28
Intestinal failure controls n = 11
Donor liver controls n = 19 P value PE and in 64% at follow-up (P = .016). Patients, who continued to display periductal a-SMA expression in the follow-up specimens, showed more progressive liver fibrosis after SPE (Metavir stage change 1 [0 to 2] versus 0 [À2 to 0], P = .054) and expansion of the ductal reaction (Table IV) .
Patients with prevailing periductal a-SMA expression also exhibited greater liver expression of collagen 1 and a-SMA as well as greater serum levels of bile acids, conjugated bilirubin, ALT, and APRI than patients without (Table IV) . Distinct progression of liver fibrosis in patients with isolated and syndromic BA. The median Metavir fibrosis stage increased significantly after SPE in isolated (2 [2] [3] (Table V) . Follow-up Metavir stage, portal inflammatory cell infiltrate, and expression of collagen and a-SMA were all significantly greater among isolated patients compared with syndromic ones. However, no significant differences were observed in gene expression of growth factors or inflammatory cytokines (data not shown). Patients with BASM tended to have lower Metavir fibrosis stage at follow-up than patients without, but the difference was not statistically significant (2 [1-2] vs 3 [2] [3] [4] , P = .072).
DISCUSSION
This is one of the first clinical studies characterizing molecular mechanisms associated with persistent liver injury following reversal of cholestasis by SPE. 19 We discovered that despite resolution of inflammation, cholestasis and hyperbilirubinemia after SPE, the livers of BA patients continue to overexpress collagen and a-SMA, which is associated with enhanced ductal reaction and PDGFA gene expression, but limited proinflammatory cytokine gene expression, compared with fibrotic and nonfibrotic pediatric controls.
Our findings show that molecular signature of liver fibrosis prevails after SPE as the expression of collagen 1 and a-SMA persists largely unchanged. Inflammatory response and proinflammatory cytokines may not have a central role in driving fibrogenesis long-term after SPE because portal Table III . Liver expression of profibrotic and inflammatory mediator genes in biliary atresia patients after a median follow-up of 3.0 years in relation to controls Gene Biliaryatresia at follow-up n = 24
Cholelithiasis controls n = 10 P value inflammatory cell infiltrate significantly reduced after PE and expression of genes encoding for several Th1 and Th2 cytokines remained unaltered or even lower than in intestinal failure controls with comparable Metavir stage. These observations further suggest that anti-inflammatory therapy may not improve native liver survival in the long-term, although corticosteroid therapy seems to promote clearance of jaundice shortly after PE, when the liver displays signs of active inflammation. 26 During cholestasis activated HSCs encircle bile ducts, and periductular myofibroblasts form portal-to-portal fibrotic septa. 12, 27 In BA, biliary epithelial cells and cells adjacent to ductal reactions express mesenchymal markers and growth factors consistent with active collagen synthesis, although the origin of these cells forming new bile ductules is unclear.
14 At PE and at the time of LTx, when patients are often severely cholestatic, a-SMA is increasingly expressed around ductular proliferations in portal areas and in fibrous septa. [28] [29] [30] [31] [32] Expression of a-SMA correlates with the extent of fibrosis in BA. 21, 29, 30, 33, 34 and increased expression of a-SMA at PE predicts impaired outcome. 21, 29, 31, 35 Accordingly, we found portally concentrated periductal a-SMA expression patterns, which tended to persist after SPE. Opposed to none of the controls, all BA patients showed periductal a-SMA at PE, but 36% lost this expression pattern at follow-up. Periductal a-SMA associated with progression of fibrosis, expansion of ductal reactions, collagen accumulation, PDGFA expression, and serum bile acid levels. These findings suggest that periductular a-SMA expression may be driven by the persisting ductal reaction and essentially contribute to the continuing fibrogenesis after SPE. Further studies addressing connections between bile acid levels, persisting ductal reaction, and liver fibrosis are needed in BA patients to explore the possibility to prevent liver injury by artificial reduction of bile acid synthesis.
Upregulated expression of PDGFA was unique to BA compared with controls, associating with increased collagen and a-SMA expression. Platelets, myofibroblasts, vascular endothelial cells and biliary epithelial cells [36] [37] [38] [39] express PDGF, which is the key growth factor in HSC activation and proliferation 13, 27 and possibly in epithelial-tomesencymal transformation. 27 Previous studies have reported increased expression of PDGFA in BA at the time of PE and LTx 36,37,39 with a correlation to fibrosis. 39 Our observations suggest an important role for PDGFA in maintaining active fibrogenesis also after SPE.
In total, 43% of our patients had structural malformations typically associated with BA, suggesting that these patients had a developmental origin of the disease. 40, 41 These syndromic patients demonstrated less deterioration in Metavir fibrosis stage, greater decrease in portal inflammation, and lower liver expression of collagen and a-SMA than patients with isolated BA. Although this finding will need to be confirmed in larger patient samples, it suggests that after SPE, fibrosis may be less progressive and potentially more responsive to interventions in syndromic patients. Based on these observations, patients should be stratified Data are median (interquartile range). Significance between groups was evaluated by Mann-Whitney U test. Bolded P-values mean that they are statistically significant (P < .05).
for isolated and syndromic disease form in future interventional studies. Our study had limitations, which include small sample size, cross-sectional design, and relatively large age variation, which provides merely associations than proof of causality. Due to the limited availability of liver specimens for obvious reasons, our control material was obtained from several different sources. Strengths of this study are inclusion of diseased and "healthy" controls and comprehensive assessment of liver fibrosis and inflammation in relation to clinical data.
In conclusion, after SPE and resolution of cholestasis, molecular signature of active fibrogenesis prevailed in the livers of BA patients. Persisting fibrogenesis was associated with a limited inflammatory response, which was even less pronounced than in patients with intestinal failure associated liver fibrosis, suggesting that anti-inflammatory therapy might not be the most promising approach to improve the long-term native liver survival in BA. The enhanced periductal smooth muscle expression associated with expansion of the ductal proliferation, progression of fibrosis, RNA expression of PDGFA, and circulating bile acid concentrations, suggesting that potential of pharmacological reduction of bile acid levels for hepatocyte protection after SPE should be addressed in future studies.
